Telomir Pharmaceuticals, Inc.
For the period ended Jul 28, 2026. Filed Jul 28, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jul 28, 2026 · Filed Jul 28, 2026
Contents
Cover page
Show cover page
DEF 14A 1 formdef14a.htm DEF 14A
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 14A
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No. )
Filed by the Registrant ☒
Filed by a party other than the Registrant ☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
|---|---|
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☒ | Definitive Proxy Statement |
| ☐ | Definitive Additional Materials |
| ☐ | Soliciting Material under § 240.14a-12 |
Telomir Pharmaceuticals, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
| ☒ | No fee required |
|---|---|
| ☐ | Fee paid previously with preliminary materials. |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11 |
Telomir Pharmaceuticals, Inc.
100 SE 2nd St, Suite 2000, #1009
Miami, Florida 33131
(786) 396-6723
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
To the Shareholders of Telomir Pharmaceuticals, Inc.:
We are pleased to invite you to attend the Annual Meeting of shareholders (the “Annual Meeting”) of Telomir Pharmaceuticals, Inc., a Florida corporation (“Telomir” or the “Company”), which will be held exclusively online via live audio-only webcast at edge.media-server.com/mmc/p/zok4x4v7 (password: telomir2026) at 11:00 a.m. Eastern Time on September 11, 2026. Telomir has chosen to hold an exclusively virtual annual meeting rather than an in-person meeting to provide for greater access for those who may want to attend. At the Annual Meeting, unless postponed or adjourned to a later date, Telomir will ask its holders of common stock, no par value, to, among other things:
| 1. | To elect four directors to the board of directors of the Company (the “Board”) to serve until the next annual meeting of shareholders or until their successors have been duly elected or appointed and qualified (“Director Election Proposal”); |
| 2. | To ratify the appointment of Salberg & Company, P.A. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (the “Auditor Appointment Proposal”); |
| 3. | To approve the adjournment of the Annual Meeting to a later date or time, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Annual Meeting, there are not sufficient votes to elect the director nominees or approve the Auditor Appointment Proposal (“Adjournment Proposal”); and |
| 4. | To conduct any other business as may properly come before the meeting or any adjournment thereof. |
The Board has fixed the close of business on July 21, 2026 (the “Record Date”) as the date for determining the shareholders entitled to notice of, and to vote at, the Annual Meeting or any adjournment thereof.
The Annual Meeting will be held virtually. If you hold your shares in an account at a brokerage firm, bank, dealer or other similar organization and wish to vote at the meeting, you will need to obtain a “legal proxy” from that entity and submit it when you register. On the day of the Annual Meeting, if you have properly registered, you may enter the meeting by clicking on the link provided and entering the password you received via email in your registration confirmation. You will be able to attend and participate in the Annual Meeting online, vote your shares electronically, and submit questions prior to and during the meeting. To vote at the meeting, (a) if you hold your shares through a bank, broker or other nominee, you will need the control number you receive by email after registering, and (b) if you hold your shares in account with our transfer agent, you will need the control number that is shown on your proxy card or email notification of the Annual Meeting.
By Order of the Board,
/s/ Erez Aminov
Erez Aminov
Chairman of the Board
Miami, Florida
July 28, 2026
Your vote is important. Whether or not you plan to participate in the Annual Meeting, please read the attached Proxy Statement and then promptly complete, date, sign and return the enclosed proxy card in order to ensure your representation and the presence of a quorum at the Meeting. You may cast your vote by visiting www.voteproxy.com. As permitted by the “Notice and Access” rules of the Securities and Exchange Commission, we are making this notice and the accompanying proxy statement, proxy card and 2025 Annual Report available to shareholders electronically via the Internet at the following website: www.eqproxyportal.com/27786/annual.
Promptly voting your shares will save us the expenses and extra work of additional solicitation. An addressed envelope for which no postage is required if mailed in the United States is enclosed if you wish to vote by mail. Submitting your proxy now will not prevent you from voting your shares at the annual meeting if you desire to do so, as your proxy is revocable at your option.
Table of Contents
| Page | |
|---|---|
| Questions and Answers Regarding the Annual Meeting of Shareholders | 4 |
| Proposal 1. Director Election Proposal | 9 |
| Proposal 2. Auditor Appointment Proposal | 15 |
| Proposal 3. Adjournment Proposal | 16 |
| Executive Compensation | 17 |
| Security Ownership of Certain Beneficial Owners and Management | 21 |
| Certain Relationships and Related Transactions | 26 |
| Report of the Audit Committee | 28 |
| Shareholder Proposals to be Presented at the Next Annual Meeting | 29 |
| Shareholders Sharing the Same Last Name and Address | 30 |
| Where You Can Find More Information | 30 |
Telomir Pharmaceuticals, Inc.
100 SE 2nd St, Suite 2000, #1009
Miami, Florida 33131
(786) 396-6723
ANNUAL MEETING OF SHAREHOLDERS
PROXY STATEMENT
This proxy statement (the “Proxy Statement”) is being sent to the holders of shares of common stock, no par value (“Common Stock”) of Telomir Pharmaceuticals, Inc., a Florida corporation (“Telomir” or the “Company”), in connection with the solicitation of proxies by our Board of Directors (the “Board”) for use at the Annual Meeting of Shareholders of the Company which will be held at 11:00 a.m. Eastern Time on September 11, 2026 (the “Annual Meeting”), virtually at the following link: edge.media-server.com/mmc/p/zok4x4v7 (password: telomir2026).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.